scholarly article | Q13442814 |
P356 | DOI | 10.1002/GCC.21975 |
P698 | PubMed publication ID | 22674490 |
P50 | author | Torsten Haferlach | Q66370751 |
Tamara Alpermann | Q66370761 | ||
Ulrike Bacher | Q66370775 | ||
Claudia Haferlach | Q66370782 | ||
Susanne Schnittger | Q66370791 | ||
P2093 | author name string | Wolfgang Kern | |
P2860 | cites work | The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia | Q27851416 |
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group | Q27851459 | ||
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia | Q27851642 | ||
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis | Q34523534 | ||
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group | Q34692984 | ||
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA | Q35596919 | ||
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia | Q35792858 | ||
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia | Q35849643 | ||
Structural and numerical variation of FLT3/ITD in pediatric AML. | Q36657987 | ||
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin | Q39821930 | ||
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor | Q39981715 | ||
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. | Q45929224 | ||
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients | Q47320656 | ||
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. | Q55035685 | ||
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2 | Q83310318 | ||
P433 | issue | 10 | |
P304 | page(s) | 910-924 | |
P577 | publication date | 2012-06-04 | |
P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
P1476 | title | Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data | |
P478 | volume | 51 |
Q28072539 | 'Acute myeloid leukemia: a comprehensive review and 2016 update' |
Q54325426 | Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3-ITD to detect patients with prognostically adverse AML. |
Q92915669 | Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design |
Q34939070 | Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies |
Q56968572 | Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia |
Q38675400 | FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions |
Q38101284 | FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance |
Q38200564 | FLT3 inhibitors in AML: are we there yet? |
Q28289859 | FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations |
Q39282600 | FLT3-ITD and its current role in acute myeloid leukaemia |
Q38892684 | FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia |
Q52366350 | FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. |
Q93023707 | Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis |
Q42361918 | Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia |
Q36823385 | Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo |
Q60950398 | Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway |
Q48161438 | Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation |
Q46576832 | Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. |
Q26799606 | Molecular Genetic Markers in Acute Myeloid Leukemia |
Q39116878 | Molecular landscape in acute myeloid leukemia: where do we stand in 2016 |
Q38664735 | Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? |
Q38154339 | Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing |
Q33798909 | Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD |
Q47965108 | Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. |
Q38216649 | The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond |
Q39045272 | The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. |
Search more.